PTC/SB/08a (08-03)
Approved for use through 07/31/2006 ONS 0651-0201
U.S. Patient and Trademask Office; U.S. DEPARTMENT OF COMMERCE
d to a collection of information unless it contains a valid OMB control number. Under the Paperwork Reduction Act of 1995, no persons are reg

	Application Number			
	Filing Date			
NFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor Simo		on Richard Daniel	
Not for submission under 37 CFR 1.99)	Art Unit			
,	Examiner Name			
	Attorney Docket Numb	er	1993-00900	

	U.S.PATENTS Remove									
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear				
	1	5400095		1995-03-21	Minich et al.					
	2 5442415 1995-08-15 Chao et al.									
	3 5944403 1999-08-31 Krause et al.									
	4	4470647		1984-09-11	Bishoff et al.					
	5						2			
If you wis	h to a	dd additional U.S. Paten			lease click the Add button.		Add			
			U.S.P	ATENT APPLI	CATION PUBLICATIONS		Remove			
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Releva	Columns, Lines where int Passages or Relevant s Appear			
	1									
If you wis	h to a	dd additional U.S. Publis	hed Ap	plication citation	n information please click the Ad	d button	Add			
	FOREIGN PATENT DOCUMENTS Remove									

Application Number | Filing Date | Filing Da

Examiner Initial*	Cite No	Foreign Number	Document 3	Country Code ² į	Kind Code ⁴	Publication Date		f Patentee or nt of cited ent	Pages,Colum where Releva Passages or Figures Appe	nt Relevant	Ts
	1										
If you wish	h to a	dd additio	nal Foreign P	atent Document	citation	information pl	ease clic	k the Add butto	n Add		
				NON-PATE	NT LITE	RATURE DO	CUMENT	s	Remove		
Examiner Initials*	aminer of the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue number(s), published, of the article (when appropriate) title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, pages(s), volume-issue number(s), published.						Тŝ				
	1										
If you wis	h to a	dd additio	nal non-pater	t literature docu	ment cit	ation informat	ion pleas	e click the Add	button Add	J '	
				EX	AMINE	R SIGNATUR	E				
Examiner	Signa	ture					Date	e Considered			
				ered, whether or considered. Incli						ough a	

See Kind Codes of USPTO Platent Documents at swee, USPTO_CODY or MEPP 601.04. Tenter office that issued the document, by the two-letter code (WIPO Standard ST3.). For Laplanese parted forcements, the advantage of the parter of the Emperor many precised the sees in universe of the parted for the parted of the parted for the Emperor many precised the sees in universe of the parted forcement by the appropriate symbols as endicated on the document under WIPO Standard ST.16 if possible. *Applicant is to place a check mark there if Emplish targuages translation is attached.*

Application Number Filing Date STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99) Application Number Filing Date Filing Date Art Unit Art Unit Examiner Name Attorney Docket Number I 1993-00000

CERTIFICATION STATEMENT

Diagon con	37	CER	1 97	and f	90	to make	a the	appropriate	colortion/c	à.

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(eVI).

ΩR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(eV).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- .7 None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

office and agriculture.								
Signature	/mwatkins/	Date (YYYY-MM-DD)	2006-06-12					
Name/Print	Marcella D. Watkins	Registration Number	36962					

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file fand by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C.12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patient and Tradenant Affice, U.S. Department of Commence, P. 0. Bot 1450, Alexandria, V.3.251.1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.3.231.1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicide is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kolfice is to process another examine your submission relation to a patient application or patient. If you do not furnish the requested process another examine your submission relation to the patient application or patient. If you do not furnish the requested the process another examines your submission, which may visually the principal purpose and for examines your submission, which may visually intermediate or of extended now about the principal purpose.

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, oursuint to 5 U.S.C. 552a(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, cuting an inspection of records concluded by GSAs and of that agency's responsibility to recommend improvements in records management practices and programs, under suthority of 4d U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 122(b) or issuance of a patent pursuant to 35 U.S. C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record via set float in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issuand patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.